On June 24, 2004, Groppi, Vincent Edward, Jr.; Jacobsen, Eric Jon; Myers, Jason Kenneth; Piotrowski, David Walter; Rogers, Bruce Nelsen; Walker, Daniel Patrick; Wishka, Donn Gregory published a patent.Product Details of 280752-78-5 The title of the patent was Preparation of N-(quinuclidinyl)heteroarylamides as nicotinic acetylcholine receptor agonists for use in combination therapy for the treatment of ADHD. And the patent contained the following:
Title N-(1-azabicyclo[2.2.2]octyl)heteroarylamides I and analogs [wherein X = o, S; R1 = H, (halo)alkyl, cycloalkyl, substituted Ph, naphthyl; R2 = independently halo, cycloalkyl, aryl, (un)substituted alkyl; m = 0-1; n = 0-1; with the proviso that m + n = 1; W = (un)substituted Ph, heterocyclyl, heteroaryl; or pharmaceutically acceptable salts, racemic mixtures, or pure enantiomers thereof] were prepared as α7 nicotinic acetylcholine receptor (nAChR) full agonists (no data). For example, reaction of phosgene with 4-bromopyrazole in EtOAc, followed by coupling with (+)-3-aminoquinuclidine•2HCl provided II•HCl (25%). The invention provides for compositions of I with psychostimulants and/or monoamine reuptake inhibitors for the treatment of attention deficit hyperactivity disorder (ADHD). The experimental process involved the reaction of (6-Bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol(cas: 280752-78-5).Product Details of 280752-78-5
The Article related to quinuclidinyl heteroarylamide preparation nicotinic acetylcholine receptor agonist adhd treatment, azabicyclooctyl heteroarylamide preparation composition nachr agonist adhd treatment and other aspects.Product Details of 280752-78-5
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts